

## DESCRIPTION




<b>Species Reactivity</b>	Mouse
<b>Specificity</b>	Detects mouse GM-CSF R $\alpha$ in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) GM-CSF R alpha or rhGM-CSF R beta is observed.
<b>Source</b>	Monoclonal Rat IgG <sub>2A</sub> Clone # 698423
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	Mouse myeloma cell line NS0-derived recombinant mouse GM-CSF R $\alpha$ Leu30-Pro327 Accession # Q00941
<b>Endotoxin Level</b>	<0.10 EU per 1 $\mu$ g of the antibody by the LAL method.
<b>Formulation</b>	Lyophilized from a 0.2 $\mu$ m filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 $\mu$ m filtered solution in PBS.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
<b>Flow Cytometry</b>	2.5 $\mu$ g/10 <sup>6</sup> cells	See Below
<b>Immunocytochemistry</b>	8-25 $\mu$ g/mL	See Below
<b>Neutralization</b>	Measured by its ability to neutralize GM-CSF-induced proliferation in the DA3 mouse myeloma cell line. Ihle, J. N. <i>et al.</i> (1984) <i>Advances in Viral Oncology</i> . In G. Klein (eds): Raven Press, New York, NY. 4:95. The Neutralization Dose (ND <sub>50</sub> ) is typically 0.02-0.12 $\mu$ g/mL in the presence of 0.1 ng/mL Recombinant Mouse GM-CSF.	

## DATA



## PREPARATION AND STORAGE

<b>Reconstitution</b>	Sterile PBS to a final concentration of 0.5 mg/mL.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>• 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>• 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>• 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

#### BACKGROUND

Granulocyte macrophage colony stimulating factor receptor alpha (GM-CSF R $\alpha$ ), also known as CD116, is a component of the receptor complex that mediates cellular responses to GM-CSF. GM-CSF promotes the differentiation and mobilization of granulocyte-macrophage, erythroid, megakaryocyte, and eosinophil progenitors. It enhances the activation of myeloid cell effector functions and plays a role in the development of Th1 biased immune responses, allergic inflammation, and autoimmunity (1-4). Mature mouse GM-CSF R $\alpha$  is an 80 kDa type I transmembrane glycoprotein that consists of a 298 amino acid (aa) extracellular domain (ECD) with two fibronectin type III domains and a juxtamembrane WSXWS motif, a 21 aa transmembrane segment, and a 40 aa cytoplasmic domain (5). Within the ECD, mouse GM-CSF R $\alpha$  shares approximately 33% and 58% aa sequence identity with human and rat GM-CSF R $\alpha$ , respectively. Soluble forms of the human receptor retain the ability to bind GM-CSF (6, 7). GM-CSF R $\alpha$  is expressed on hematopoietic stem cells, progenitor and differentiated cells in the myeloid lineage, vascular endothelial cells, placenta, and non-hematopoietic solid tumor cells (8). GM-CSF R $\alpha$  associates with the common beta chain/CD131 ( $\beta_c$ ), a 135 kDa transmembrane protein that is also the signal transducing component of the receptors for IL-3 and IL-5 (9, 10). Association with  $\beta_c$  converts GM-CSF R $\alpha$  from a low affinity to a high affinity receptor for GM-CSF (9-11). The shared usage of  $\beta_c$  underlies the synergism between GM-CSF, IL-3, and IL-5 in their effects on myeloid cell differentiation and activation (1, 2).

#### References:

1. Martinez-Moczygemba, M. and D.P. Huston (2003) *J. Allergy Clin. Immunol.* **112**:653.
2. Fleetwood, A.J. *et al.* (2005) *Crit. Rev. Immunol.* **25**:405.
3. Eksioglu, E.A. *et al.* (2007) *Exp. Hematol.* **35**:1163.
4. Cao, Y. (2007) *J. Clin. Invest.* **117**:2362.
5. Park, L.S. *et al.* (1992) *Proc. Natl. Acad. Sci.* **89**:4295.
6. Pelley, J.L. *et al.* (2007) *Exp. Hematol.* **35**:1483.
7. Raines, M.A. *et al.* (1991) *Proc. Natl. Acad. Sci.* **88**:8203.
8. Chiba, S. *et al.* (1990) *Cell Regul.* **1**:327.
9. Kitamura, T. *et al.* (1991) *Proc. Natl. Acad. Sci.* **88**:5082.
10. Hayashida, K. *et al.* (1990) *Proc. Natl. Acad. Sci.* **87**:9655.
11. Hoang, T. *et al.* (1993) *J. Biol. Chem.* **268**:11881.